RNAC
Cartesian Therapeutics Inc.
NASDAQ: RNAC · HEALTHCARE · BIOTECHNOLOGY
$6.22
-3.86% today
Updated 2026-04-30
Market cap
$199.26M
P/E ratio
—
P/S ratio
71.24x
EPS (TTM)
$-5.02
Dividend yield
—
52W range
$6 – $16
Volume
0.2M
Cartesian Therapeutics Inc. (RNAC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-2,317.00%
ROE
-7,029.00%
ROA
-14.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2014 | $3.04M | $-12.88M | 100.00% | -506.55% | -423.68% |
| 2015 | $6.01M | $-25.17M | 100.00% | -420.96% | -418.80% |
| 2016 | $8.08M | $-36.21M | 100.00% | -428.92% | -447.98% |
| 2017 | $207000.00 | $-65.32M | 100.00% | -30,813.53% | -31,556.04% |
| 2018 | $903000.00 | $-65.34M | 100.00% | -7,200.66% | -7,235.44% |
| 2019 | $6.68M | $-55.35M | 100.00% | -785.61% | -828.97% |
| 2020 | $16.60M | $-68.88M | 100.00% | -342.36% | -414.99% |
| 2021 | $85.08M | $-25.69M | 100.00% | -5.40% | -30.19% |
| 2022 | $110.78M | $35.38M | 98.16% | 13.12% | 31.94% |
| 2023 | $26.00M | $-219.71M | 100.00% | -332.32% | -844.91% |
| 2024 | $38.91M | $-77.42M | 100.00% | -112.81% | -198.97% |
| 2025 | $2.80M | $-130.30M | 100.00% | -3,099.93% | -4,658.63% |